ERIS.NS Balance Sheet
Eris Lifesciences Ltd.
Profit & Loss Balance Sheet Cash Flow
Balance Sheet · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-24 01:34
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Property, Plant and Equipment | ₹356.00 Cr. | ₹504.60 Cr. | ₹662.07 Cr. | ₹708.37 Cr. | PropertyPlantAndEquipment |
| Capital Work-in-Progress | ₹21.38 Cr. | ₹19.06 Cr. | ₹66.74 Cr. | ₹171.47 Cr. | CapitalWorkInProgress |
| Goodwill | ₹331.85 Cr. | ₹861.21 Cr. | ₹911.97 Cr. | ₹911.97 Cr. | Goodwill |
| Other Intangible Assets | ₹1,880.25 Cr. | ₹2,961.71 Cr. | ₹3,732.44 Cr. | ₹3,567.22 Cr. | OtherIntangibleAssets |
| Non-current Investments | ₹6.69 Cr. | ₹15.54 Cr. | ₹10.51 Cr. | ₹9.98 Cr. | NoncurrentInvestments |
| Other Non-current Assets | ₹23.53 Cr. | ₹66.72 Cr. | ₹34.22 Cr. | ₹151.21 Cr. | OtherNoncurrentAssets |
| Total Non-current Assets | ₹2,902.61 Cr. | ₹4,746.76 Cr. | ₹5,770.64 Cr. | ₹5,825.66 Cr. | NoncurrentAssets |
| Inventories | ₹131.44 Cr. | ₹189.03 Cr. | ₹334.83 Cr. | ₹436.82 Cr. | Inventories |
| Trade Receivables | ₹292.71 Cr. | ₹422.02 Cr. | ₹458.64 Cr. | ₹680.34 Cr. | TradeReceivablesCurrent |
| Cash and Cash Equivalents | ₹56.02 Cr. | ₹94.25 Cr. | ₹199.74 Cr. | ₹54.74 Cr. | CashAndCashEquivalents |
| Current Investments | ₹30.01 Cr. | ₹0.00 Cr. | ₹5.00 Cr. | ₹0.00 Cr. | CurrentInvestments |
| Other Current Assets | ₹247.35 Cr. | ₹282.61 Cr. | ₹192.73 Cr. | ₹293.56 Cr. | OtherCurrentAssets |
| Total Current Assets | ₹764.72 Cr. | ₹2,302.07 Cr. | ₹1,262.53 Cr. | ₹1,539.85 Cr. | CurrentAssets |
| Total Assets | ₹3,667.33 Cr. | ₹7,048.84 Cr. | ₹7,033.17 Cr. | ₹7,365.51 Cr. | Assets |
| Equity Share Capital | ₹13.60 Cr. | ₹13.60 Cr. | ₹13.62 Cr. | ₹13.85 Cr. | EquityShareCapital |
| Other Equity | ₹2,182.39 Cr. | ₹2,572.52 Cr. | ₹2,840.74 Cr. | ₹3,888.82 Cr. | OtherEquity |
| Equity Attributable to Owners | ₹2,195.99 Cr. | ₹2,586.12 Cr. | ₹2,854.36 Cr. | ₹3,902.67 Cr. | EquityAttributableToOwnersOfParent |
| Non-controlling Interests | ₹24.69 Cr. | ₹635.91 Cr. | ₹417.40 Cr. | ₹-7.01 Cr. | NonControllingInterest |
| Total Equity | ₹2,220.68 Cr. | ₹3,222.03 Cr. | ₹3,271.76 Cr. | ₹3,895.66 Cr. | Equity |
| Long-term Borrowings | ₹644.45 Cr. | ₹654.51 Cr. | ₹1,781.72 Cr. | ₹955.83 Cr. | BorrowingsNoncurrent |
| Total Non-current Liabilities | ₹1,003.42 Cr. | ₹1,294.73 Cr. | ₹2,380.02 Cr. | ₹1,392.75 Cr. | NoncurrentLiabilities |
| Short-term Borrowings | ₹185.57 Cr. | ₹2,080.76 Cr. | ₹696.20 Cr. | ₹1,353.85 Cr. | BorrowingsCurrent |
| Trade Payables | ₹124.77 Cr. | ₹268.35 Cr. | ₹332.35 Cr. | ₹329.65 Cr. | TradePayablesCurrent |
| Other Current Liabilities | ₹21.72 Cr. | ₹48.96 Cr. | ₹66.00 Cr. | ₹71.64 Cr. | OtherCurrentLiabilities |
| Total Current Liabilities | ₹443.23 Cr. | ₹2,532.08 Cr. | ₹1,381.39 Cr. | ₹2,077.10 Cr. | CurrentLiabilities |
| Total Equity and Liabilities | ₹3,667.33 Cr. | ₹7,048.84 Cr. | ₹7,033.17 Cr. | ₹7,365.51 Cr. | EquityAndLiabilities |
Every figure above is the exact value of the named XBRL element from ERIS.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).